Expression and clinical significance of WWOX, Elf5, Snail1 and EMT related factors in epithelial ovarian cancer

Abstract

Expression and clinical significance of WW domain-containing oxidoreductase (WWOX), Elf5, Snail1 and epithelial-mesenchymal transition (EMT) related factors in epithelial ovarian cancer were investigated. Ovarian cancer tissues of 300 epithelial ovarian cancer patients and the adjacent normal tissues were analyzed. Immunohistochemical method was used to detect the expressions of WWOX, Elf5, Snail1 and EMT marker molecules in the specimens. The relationship between the indicators and clinicopathological parameters, and prognosis of patients with ovarian cancer was analyzed. The relationship between WWOX, Elf5, Snail1 and EMT marker molecules E-cadherin, N-cadherin and vimentin in ovarian cancer tissues was analyzed. The expression levels of WWOX, Elf5, Snail1 and EMT marker molecules in epithelial ovarian cancer tissues were significantly different from those in adjacent normal tissues, and were related to surgical pathological stage, pathological grade and lymph node metastasis. High expressions of WWOX and Elf5 were related to the survival rate of patients. The survival rate of patients with positive expression was significantly higher than that of negative expression. FIGO stage, pathological grade, lymph node metastasis and expression of WWOX and Elf5 were all independent factors affecting postoperative prognosis in ovarian cancer patients. In conclusion, the expression levels of WWOX, Elf5, Snail1 and EMT related factors in epithelial ovarian cancer tissues are consistent and different. The expression levels of WWOX and Elf5 are related to the survival and prognosis of patients with epithelial ovarian cancer.

An integrative multi-omics network-based approach identifies key regulators for breast cancer

“…CDK6 and MLLT10 have been identified as cancer driver genes according to the COSMIC database. By manually checking in the PubMed, 7 of the top 20 genes were reported to be relevant to ovarian cancer, including MAPT [55] , BECN1 [56] , PRC1 [57] , CBX1 [58] , CDK6 [59] , WWOX [60] , and PNPO [61] . We performed KEGG pathway enrichment analysis for the top 100 genes ( Figure Supplementary Fig.…”

ELF5 promotes non-small cell lung cancer cell proliferation through regulating the expression of APC2

“…Although previous studies have assessed ELF5 in a variety of cancers [3][4][5][6][7], there have been no reports determining relevance of ELF5 in lung cancer tissues and its clinicopathological signi cance. In the present study, we dissected that ELF5 expression in lung adenocarcinoma was signi cantly higher than that in corresponding adjacent normal tissues, which suggests ELF5 may play an important role in the development of lung adenocarcinoma.…”

“…Increasing evidence reveals that ELF5 plays a tumour suppressive role in prostate [3,4], bladder [5] and ovarian [6] cancer. It was found that expression of Elf5 was low in ovarian cancer tissues, and highly expressed in adjacent tissues, indicating that the low expression of Elf5 may be closely related to the occurrence of ovarian cancer [7]. Both tumour promoting and suppressive roles for ELF5 have been reported in breast cancer, which may be linked to the subtype of the disease.…”

E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer

“…A summary of the results described in the remaining 14 studies is presented in Table 4. Five studies showed that G3 ovarian cancer was characterized by significantly lower E-cadherin expression than the G1 and G2 types [25,32,49,52,54]. In contrast, six articles showed that positive as well as negative/reduced immunoreactivity of E-cadherin was at a similar level independent of ovarian tumor grading [43,51,53,55,57,58].…”

“…Two papers were rejected after the first analysis due to (i) enrollment of only FIGO III or IV stage patients [34] and (ii) matching FIGO II with FIGO III/IV patients [50]. As presented in Table 2, 9 of the remaining 13 articles showed that the tumor tissue of EOC patients with FIGO III and IV stages expressed significantly less E-cadherin than the tumor tissue of patients with early stages (FIGO I and II) of disease [25,26,43,[51][52][53][54][55][56]. Nonetheless, four studies did not confirm the association of reduced E-cadherin expression with the advancement of disease and showed similar protein immunoreactivity in tumor tissue from patients in all cancer stages [32,49,57,58].…”